Cisplatin-Paclitaxel-Cyclophosphamide with G-CSF in Primary Advanced Epithelial Ovarian Cancer

By Fanning J.   Colgrove M.   Phibbs G.  

Gynecologic Oncology, Vol. 79, Iss. 1, 2000-10 ,pp. : 97-100

Elsevier

Access to resources Recommend Favorite

Correlation of Drug Response with the ATP Tumorchemosensitivity Assay in Primary FIGO Stage III Ovarian Cancer

By Konecny G.   Crohns C.   Pegram M.   Felber M.   Lude S.   Kurbacher C.   Cree I.A.   Hepp H.   Untch M.  

Gynecologic Oncology, Vol. 77, Iss. 2, 2000-05 ,pp. : 258-263

Elsevier

Access to resources Recommend Favorite

Breast Cancer Survival and in Vitro Tumor Response in the Extreme Drug Resistance Assay

By Mehta R.S.  

Breast Cancer Research and Treatment, Vol. 66, Iss. 3, 2001-04 ,pp. : 225-237

Springer Publishing Company

Access to resources Recommend Favorite

A Phase I Study of Paclitaxel, Doxorubicin, and Cisplatin in Patients with Previously Untreated Epithelial Ovarian Cancer

By Naumann R.W.   Alvarez R.D.   Omura G.A.   Segars E.   Kilgore L.C.   Partridge E.E.  

Gynecologic Oncology, Vol. 71, Iss. 3, 1998-12 ,pp. : 450-453

Elsevier

Access to resources Recommend Favorite

Intraperitoneal Cisplatin and Intravenous Paclitaxel in the Treatment of Epithelial Ovarian Cancer Patients with a Positive Second Look

By Makhija S.   Sabbatini P.   Aghajanian C.   Venkatraman E.   Spriggs D.R.   Barakat R.  

Gynecologic Oncology, Vol. 79, Iss. 1, 2000-10 ,pp. : 28-32

Elsevier

Access to resources Recommend Favorite